10-K: Denali Therapeutics (DNLI) Files 10-K: BLA Submission Planned for Hunter Syndrome Drug

Denali Therapeutics plans to submit a BLA for its Hunter Syndrome drug in early 2025 and is preparing for a potential commercial launch.

Summary

• Denali Therapeutics is focused on developing therapies for neurodegenerative and lysosomal storage diseases, utilizing its Transport Vehicle (TV) technology to cross the blood-brain barrier (BBB).
• The company plans to submit a Biologics License Application (BLA) for tividenofusp alfa (DNL310) for Mucopolysaccharidosis II (MPS II or Hunter syndrome) in early 2025, with a potential commercial launch in late 2025 or early 2026.
• Denali's clinical development portfolio includes DNL126 for MPS IIIA (Sanfilippo syndrome) and DNL593 for frontotemporal dementia-granulin (FTD-GRN).
• Small molecule programs include BIIB122/DNL151 for Parkinson's disease and DNL343 for amyotrophic lateral sclerosis (ALS).
• The company has collaborations with Biogen, Takeda, and Sanofi.
• As of December 31, 2024, Denali had approximately $1.19 billion in cash, cash equivalents, and marketable securities.
• The company anticipates advancing one to two new molecule entities (NMEs) into clinical development over the next three years, starting in 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments regarding clinical trials and regulatory designations, the company also faces challenges such as trial failures, collaboration terminations, and increasing net losses. The overall sentiment is cautiously optimistic, reflecting the inherent risks and uncertainties in the biopharmaceutical industry.

Positives

• FDA agreement reached on CSF heparan sulfate as a surrogate endpoint for accelerated approval of tividenofusp alfa in MPS II.
• Positive preclinical data supports DNL126 for MPS IIIA, showing improved lysosomal and microglial morphology, neurodegeneration, and cognitive function.
• Phase 1/2 study of TAK-594/DNL593 in healthy subjects showed substantial increases in CSF PGRN levels, suggesting brain delivery was achieved.
• Collaboration with a third party provides committed funding of $75.0 million for a Phase 2a study of BIIB122/DNL151 in LRRK2-associated Parkinson's disease.
• Preclinical studies with ATV:Abeta have demonstrated potential for better efficacy and safety compared to a standard antibody, with superior plaque reduction and very low rates of amyloid related imaging abnormalities (ARIA).

Negatives

• The Phase 2/3 HEALEY ALS Platform Trial evaluating DNL343 for ALS did not meet the primary and key secondary endpoints.
• Biogen terminated its license to the ATV:Abeta program, resulting in no future milestone or royalty payments from Biogen related to the program.
• Sanofi discontinued the K2 Phase 2 study evaluating SAR443820/DNL788 in participants with multiple sclerosis, and terminated the CNS Products program.
• Takeda terminated the ATV:TREM2 program after mutual agreement to discontinue preclinical activities.
• The company has incurred significant net losses since its inception and anticipates that it will continue to incur net losses for the foreseeable future.

Risks

• The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable.
• Clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate substantial evidence of the safety and efficacy or potency of product candidates.
• The company faces significant competition and its operating results may suffer if it fails to compete effectively.
• The company depends on collaborations with third parties for the research, development and commercialization of certain product candidates.
• The company relies on third parties to conduct its clinical trials and some aspects of its research and preclinical testing, and those third parties may not perform satisfactorily.
• The company relies on third parties for the manufacture of the significant majority of the materials for its research programs, preclinical studies, and clinical trials.
• The company depends on third-party suppliers for key raw materials used in its manufacturing processes, and the loss of these suppliers or their inability to supply the company with adequate raw materials could harm its business.
• If the company is unable to obtain and maintain patent protection for its product candidates or its TV technology, its competitors could develop and commercialize products or technology similar or identical to ours.
• If the company is not successful in attracting, motivating and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.
• The company's internal computer systems, or those used by its collaborators, CROs or other contractors, may fail or suffer security breaches or incidents that could compromise the confidentiality, integrity, and availability of such systems and data, expose the company to liability, and affect its reputation.
• The market price of the company's common stock has been and may continue to be volatile, which could result in substantial losses for investors.

Future Outlook

Denali expects to advance one to two new molecule entities (NMEs) into clinical development over the next three years, beginning in 2025, and is preparing for a potential U.S. commercial launch of tividenofusp alfa in late 2025 or early 2026.

Industry Context

The report highlights the competitive landscape of the biotechnology and pharmaceutical industries, particularly in the neurodegenerative disease field, with numerous companies developing therapies for Alzheimer's, Parkinson's, ALS, and lysosomal storage diseases.

Comparison to Industry Standards

• The document mentions competing treatments for Alzheimer's Disease including Aduhelm (Biogen), LEQEMBI (Eisai/Biogen), and Kisunla (Eli Lilly).
• The document mentions competing treatments for ALS including Radicava (Mitsubishi Tanabe Pharma) and Qalsody (Biogen).
• The document mentions that various BBB-penetrant and direct to CNS delivered ERTs and gene therapies are being developed by several large and specialty pharmaceutical and biotechnology companies, including JCR Pharmaceuticals, RegenxBio, Kyowa Kirin/Orchard Therapeutics, and Ultragenyx in various stages of development.

Stakeholder Impact

• Positive impact on patients with MPS II if tividenofusp alfa is approved and launched.
• Potential benefits for patients with MPS IIIA, FTD-GRN, Parkinson's disease, and ALS through ongoing clinical trials.
• Potential dilution for existing stockholders if additional capital is raised through equity offerings.

Next Steps

• Submit BLA for tividenofusp alfa in MPS II under the accelerated approval pathway in early 2025.
• Continue dosing in Part B of the Phase 1/2 study in FTD-GRN.
• Complete enrollment of the Phase 2b LUMA study in early-stage PD.
• Continue enrollment in the Phase 2a study in PD related to pathogenic variants of LRRK2.
• Further analyses from Regimen G (DNL343) in Phase 2/3 HEALEY ALS Platform Trial.
• Continue Phase 2 UC study.
• Seek alignment with the FDA on an accelerated approval pathway for DNL126 for MPS IIIA.

Key Dates